HOUSTON, Oct. 14 /PRNewswire/ -- OrthoAccel Technologies, Inc., developers of the AcceleDent System, an acceleration device to enhance orthodontics, announced this week that it has engaged Todd Cooper as a Director on its Corporate Board. Mr. Cooper's directorship will involve oversight and corporate governance of the Company's business strategy, with a focus on market growth.
AcceleDent is a simple, removable dental device that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement. A Phase I clinical trial in 2008 in Houston, Texas demonstrated the safety of the device. The first completed AcceleDent case in private practice was documented earlier this month in the United Kingdom.
Mr. Cooper's background is particularly relevant to OrthoAccel's development of the AcceleDent brand. His extensive experience includes general management, sale, marketing and product development on a global basis. While at Discus, a market leader across numerous dental aesthetic product categories, his leadership resulted in aggressive revenue growth and increasing profitability. Most recently, Mr. Cooper managed the $400 million medical surgical business at Henry Schein, a $6.5 billion life sciences company.
Michael Lowe, CEO of OrthoAccel, commented, "We knew immediately that Todd's insight could help us shape our strategic direction. There are many important parallels between OrthoAccel and the businesses that he has successfully managed in the past." Mr. Cooper remarked, "AcceleDent can revolutionize the orthodontic market space and has huge market potential globally, much like Discus' whitening products did in the aesthetic space. AcceleDent addresses the fundamental desire by patients to shorten the time they need to use orthodontic appliances. I look forward to actively working with the Board and Management Team to build a strong global business."
Last month, OrthoAccel attended the British Orthodontic Conference, where it hosted a reception to feature the learnings from a select group of orthodontic specialist doctors who had been using the product for about a year. Later this month, a lecture series will be held in Australia, where the device is also available, to further generate awareness around the AcceleDent science and favorable clinical outcomes. This event is being coordinated in conjunction with AB Orthodontics, the exclusive distributor of AcceleDent in Australia.
OrthoAccel is nearing conclusion of another US clinical trial at the UT Health Science Center in San Antonio with an anticipated completion date in 2010.
About OrthoAccel Technologies, Inc.
Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.
About the AcceleDent System
AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at www.acceledent.com or requested via email@example.com
SOURCE OrthoAccel Technologies, Inc.